TOKYO -- Japanese trading house Mitsui & Co. plans to increase fivefold its investments in medical startups over the next three years, with a focus in Southeast Asian companies, Nikkei has learned.
Pharmaceuticals
Mitsui to expand health startup investment with focus on ASEAN
Trading house plans fivefold funding rise, sees technology as solution
A molecular diagnostic laboratory in Singapore operated by Mirxes, a Singapore-headquartered company that has developed the world's first molecular blood test for the early detection of gastric cancer. Mitsui & Co. invested as a shareholder in the company's latest fundraising round. (Courtesy of Mirxes)
Read Next
Latest on Pharmaceuticals
